Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in AUD (TTM)119.62k
- Net income in AUD-42.72m
- Incorporated1987
- Employees19.00
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 91.70m | -- | -- | 9.73 | -- | 65.05 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 96.07m | -- | -- | 6.65 | -- | 500.13 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| LTR Pharma Ltd | 49.00k | -6.95m | 125.49m | -- | -- | 70.17 | -- | 2,560.98 | -0.0499 | -0.0499 | 0.0004 | 0.0211 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14,192.84 | -- | -- | -414.02 | 0.00 | -- | -- | -- | -378.00 | -- | -- | -- |
| Cogstate Ltd | 65.03m | 8.16m | 166.60m | 61.00 | 20.43 | 2.69 | 13.59 | 2.56 | 0.0472 | 0.0472 | 0.3757 | 0.3588 | 0.7762 | -- | 4.96 | -- | 9.74 | 8.45 | 12.51 | 12.30 | 55.96 | 53.13 | 12.55 | 10.75 | -- | -- | 0.0162 | 0.00 | 7.36 | 14.72 | 52.75 | -- | -5.00 | -- |
| Arovella Therapeutics Ltd | 155.73k | -8.75m | 200.69m | 14.00 | -- | 17.78 | -- | 1,288.68 | -0.0093 | -0.0093 | 0.0002 | 0.0107 | 0.0166 | -- | 30.42 | -- | -93.26 | -78.61 | -116.36 | -96.29 | 100.00 | 51.81 | -5,616.16 | -2,126.97 | -- | -1,012.45 | 0.00 | -- | -64.27 | -34.07 | 14.10 | -- | -37.76 | -- |
| Dimerix Ltd | 583.48k | -17.08m | 225.72m | 0.00 | -- | 12.25 | -- | 386.85 | -0.0373 | -0.0373 | 0.0013 | 0.0331 | 0.0234 | -- | 0.0612 | -- | -68.53 | -71.97 | -98.37 | -113.16 | -- | -- | -2,926.42 | -8,332.83 | -- | -- | 0.0082 | -- | 1,485.97 | 100.27 | -23.71 | -- | 17.99 | -- |
| Race Oncology Ltd | 832.58k | -13.82m | 268.49m | -- | -- | 14.65 | -- | 322.49 | -0.0839 | -0.0839 | 0.0051 | 0.1075 | 0.0355 | -- | 0.9201 | -- | -58.97 | -46.49 | -63.04 | -48.68 | -- | -- | -1,659.82 | -2,995.74 | -- | -- | 0.00 | -- | 40.68 | 116.86 | -39.26 | -- | -- | -- |
| Imugene Ltd | 0.00 | -149.68m | 342.16m | 0.00 | -- | 2.85 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
| Immutep Ltd | 119.62k | -42.72m | 421.82m | 19.00 | -- | 2.24 | -- | 3,526.37 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
| PYC Therapeutics Ltd | 22.86m | -37.73m | 933.22m | 23.00 | -- | 11.73 | -- | 40.83 | -0.0094 | -0.0094 | 0.0057 | 0.017 | 0.356 | -- | 97.03 | -- | -59.36 | -45.92 | -69.52 | -52.18 | -- | -- | -166.75 | -167.45 | -- | -69.18 | 0.0135 | -- | 43.85 | 882.22 | -65.54 | -- | -7.67 | -- |
| Opthea Ltd | 186.69k | -329.80m | 1.00bn | 5.00 | -- | -- | -- | 5,374.46 | -0.5173 | -0.5173 | 0.0003 | -0.104 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
| Mesoblast Ltd | 8.84m | -131.71m | 1.59bn | 73.00 | -- | 2.21 | -- | 180.22 | -0.1312 | -0.1312 | 0.009 | 0.6303 | 0.0088 | -- | 3.21 | 121,067.80 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
Data as of Nov 08 2024. Currency figures normalised to Immutep Ltd's reporting currency: Australian Dollar AUD
36.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 20 Sep 2024 | 153.86m | 10.59% |
| MLC Investments Ltd.as of 20 Sep 2024 | 73.08m | 5.03% |
| Perennial Value Management Ltd.as of 16 Aug 2024 | 71.74m | 4.94% |
| Milford Asset Management Ltd.as of 13 Feb 2024 | 62.12m | 4.28% |
| IOOF Investment Services Ltd.as of 20 Sep 2024 | 55.35m | 3.81% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Sep 2024 | 52.60m | 3.62% |
| Vanguard Investments Australia Ltd.as of 30 Sep 2024 | 22.61m | 1.56% |
| Antares Capital Partners Ltd.as of 20 Sep 2024 | 14.64m | 1.01% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 11.54m | 0.80% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 10.95m | 0.75% |
More ▼
Data from 30 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
